ACTUALITES

SÉMINAIRES

ÉVÉNEMENTS

  • 2ème Symposium IRCI / 21-23 Juin 2020

La seconde édition du Symposium International IRCI (Immune Responses in Cancer and Infection) a été reportée à juin 2021 à l'Espaces Charles Mérieux, ENS Lyon.

Coorganisé par des chercheurs du Centre de Recherche en Cancérologie de Lyon et du Centre International de Recherche en Infectiologie, cet événement rassemblera la communauté scientifique intéressée par les dernières avancées dans le domaine de l’immunologie des cancers et des infections.

Le programme scientifique est axé autour de 6 sessions thématiques et des interventions de 20 conférenciers invités de renommée internationale tels que le Pr. Harald Zur Hausen (DKFZ, Allemagne), Prix Nobel de Médecine 2008 et le Pr. Ruslan Medzhitov (Yale University, Etats-Unis).

Pour plus d'informations, rendez-vous sur : https://irci2021.insight-outside.fr/

DIVERS

DERNIÈRES PUBLICATIONS

  • Failed Apoptosis Enhances Melanoma Cancer CellAggressiveness

Triggering apoptosis remains an efficient strategy to treat cancer. However, apoptosis is no longer a final destination since cancer cells can undergo failed apoptosis without dying. Recent evidence shows that limited mitochondrial permeabilization and non-lethal caspase activation occur under certain circumstances, although it remains unclear how failed apoptosis affects cancer cells. Using an original cancer cell model to trigger non-lethal caspase activation, we find that melanoma cancer cells undergoing failed apoptosis have a particular transcriptomic signature associated with focal adhesions, transendothelial migration, and modifications of the actin cytoskeleton. In line with this, cancer cells surviving apoptosis gain migration and invasion properties in vitro and in vivo. We further demonstrate that failed apoptosis-associated gain in invasiveness is regulated by the c-Jun N-terminal kinase (JNK) pathway, whereas its RNA sequencing signature is found in metastatic melanoma. These findings advance our understanding of how cell death can both cure and promote cancer. 

  • Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling

In mouse embryonic stem cells (mESCs), chemical blockade of Gsk3α/β and Mek1/2 (2i) instructs a self-renewing ground state whose endogenous inducers are unknown. Here we show that the axon guidance cue Netrin-1 promotes naive pluripotency by triggering profound signalling, transcriptomic and epigenetic changes in mESCs. Furthermore, we demonstrate that Netrin-1 can substitute for blockade of Gsk3α/β and Mek1/2 to sustain self-renewal of mESCs in combination with leukaemia inhibitory factor and regulates the formation of the mouse pluripotent blastocyst. Mechanistically, we reveal how Netrin-1 and the balance of its receptors Neo1 and Unc5B co-regulate Wnt and MAPK pathways in both mouse and human ESCs. Netrin-1 induces Fak kinase to inactivate Gsk3α/β and stabilize β-catenin while increasing the phosphatase activity of a Ppp2r2c-containing Pp2a complex to reduce Erk1/2 activity. Collectively, this work identifies Netrin-1 as a regulator of pluripotency and reveals that it mediates different effects in mESCs depending on its receptor dosage, opening perspectives for balancing self-renewal and lineage commitment.

https://doi.org/10.1038/s41556-020-0483-2

OFFRES D'EMPLOI

  • September 2020 - Assistant ingénieur

L'équipe « Virus hépatiques et pathobiologie des maladies chroniques hépatiques », dir. Fabien Zoulim recherche un assistant ingénieur. Le sous-groupe dirigé par le Dr Barbara Testoni, auquel le/la candidat-e sera rattaché-e s’intéresse particulièrement aux mécanismes moléculaires contrôlant l’activité transcriptionnelle du minichromosome viral.
Plus d'information

  • September 2020 - Project manager in immunology

The Laboratory of Immunotherapy of Cancer of Lyon (LICL) is currently seeking a talented and experienced immunologist to coordinate the scientific and technological projects within the lab.
The LICL (head: C. Caux) is affiliated to the Cancer Research Center of Lyon (CRCL) and to the department of Translational Research and Innovation of the comprehensive Léon Bérard cancer Center (CLB) at the interface between fundamental research developed within the CRCL immunology teams and the clinical research implemented by the CLB clinical teams.
More information

  • August 2020 - 2 postdoctoral positions in non-coding RNAs, Translation, Cancer & Metastasis

Two junior post-doctoral positions are open to work on an innovative joint research program between LyOS and CRCL in Lyon, France. The program aims to investigate the translational control mediated by tumour-derived non-coding RNAs on the nesting of disseminated tumour cells in the bone marrow.
More information

  • Juillet 2020 - Ingénieur d'étude

Dans le cadre d'un projet européen, l'équipe "Anticorps Anticancer" du CRCL et l'équipe "Gepharm" du LAGEPP recherchent un ingénieur d'étude en biologie cellulaire.
Plus d'informations

  • July 2020 - Postdoctoral position

The laboratory of Prof Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-b on T cell-biology. A particular focus is proposed on deciphering mechanisms of action of TGF-b in controlling skin inflammation using both in vitro and in vivo mouse models.
More Information

  • January 2020 - Post-doctoral position

The laboratory of Dr. Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-B on T cell-biology.
More information

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :